2022
Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction
Park D, An S, Attanasio S, Jolly N, Malhotra S, Doukky R, Samsky M, Sen S, Ahmad T, Nanna M, Vij A. Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. The American Journal Of Cardiology 2022, 187: 84-92. PMID: 36459752, PMCID: PMC10958453, DOI: 10.1016/j.amjcard.2022.10.026.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBayes TheoremDeathHeart FailureHumansHypotensionNeprilysinNetwork Meta-AnalysisRandomized Controlled Trials as TopicReceptors, AngiotensinStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsAngiotensin receptor neprilysin inhibitorAngiotensin receptor blockersReduced ejection fractionHeart failureEjection fractionHigh riskCause mortalityReceptor blockersCardiac deathLower riskEnzyme inhibitorsMajor adverse cardiac eventsAngiotensin converting enzyme (ACE) inhibitorsAdverse cardiac eventsEfficacy end pointNetwork meta-analysis approachImproved clinical outcomesRandomized clinical trialsP scoreCardiac eventsAngiotensin receptorsClinical outcomesNeprilysin inhibitorClinical benefitRecent trialsChoice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial
Wang SY, Hanna JM, Gongal P, Onuma O, Nanna MG. Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial. American Heart Journal 2022, 254: 30-34. PMID: 35932912, PMCID: PMC10908340, DOI: 10.1016/j.ahj.2022.07.006.Peer-Reviewed Original ResearchMeSH KeywordsAmlodipineAntihypertensive AgentsChlorthalidoneHumansHypertensionIsolated Systolic HypertensionLisinoprilTreatment OutcomeConceptsDiastolic hypertensionSystolic hypertensionAntihypertensive agentsSecondary analysisPrevent Heart Attack TrialBroad treatment recommendationsDifferent antihypertensive agentsUse of chlorthalidoneLipid-Lowering TreatmentHeart Attack TrialCoronary heart diseaseCause mortalityPrimary outcomeAttack TrialALLHAT trialHeart diseaseTreatment recommendationsHypertensionPatientsTrialsAntihypertensivesAmlodipineLisinoprilStrokeAgents
2020
Can the Absence of Hypertension Refine the Risk Assessment of Older Adults for Future Cardiovascular Events?
Nanna MG, Navar AM, Wojdyla D, Nelson AJ, Sullivan AE, Peterson ED. Can the Absence of Hypertension Refine the Risk Assessment of Older Adults for Future Cardiovascular Events? The American Journal Of Cardiology 2020, 142: 83-90. PMID: 33279483, PMCID: PMC8221431, DOI: 10.1016/j.amjcard.2020.11.027.Peer-Reviewed Original ResearchConceptsSystolic blood pressureAtherosclerotic cardiovascular diseaseAbsence of hypertensionBlood pressureCardiovascular diseaseCardiovascular eventsEvent ratesOlder adultsLower CVD event ratesLower systolic blood pressureASCVD event ratesCVD event ratesDiastolic blood pressureFuture cardiovascular eventsASCVD riskRisk stratificationPooled cohortMultivariable modelingHypertensionRisk scoreLower riskRisk estimatesNational InstituteObserved event ratesAdults